INTERIM REPORT CHRONTECH PHARMA JANUARY-MARCH 2011

INTERIM REPORT CHRONTECH PHARMA JANUARY-MARCH 2011


  · Research and development costs amounted to SEK 3.8 (1.8) m
  · The loss after tax was SEK -5.0 (-2.7) m
  · Earnings per share were SEK -0.06 (-0.04)
  · The company had no net sales for the period
  · Of six patients with genotype 1 chronic hepatitis C virus infection
treated with standard of care treatment following participation in a
clinical trial with four ChronVac-C® vaccinations, five have been cured,
i.e. are virus free six months after completed treatment. These are
unusually good treatment results for patients carrying the hard-to-treat
variant of hepatitis C-virus called genotype 1.
  · ChronTech has received permission for starting a controlled phase
IIb clinical study of ChronVac-C® in combination with standard-of-care
  · ChronTech has entered as a partner in a collaborative project to
improve on HCV vaccines with Karolinska Institutet, University of
Gothenburg, and Vecura, which is funded by Vinnova by up to SEK 4.5 m.
The project started in November 2010 and lasts for three years.  

Events after the end of the reporting period

  · ChronTech Pharma AB has signed a collaboration agreement with
Transgene S.A. (Euronext Paris: FR0005175080) and Inovio
Pharmaceuticals, Inc. (NYSE Amex: INO) to evaluate a novel therapeutic
vaccination strategy against genotype 1 hepatitis C virus (HCV) in a
phase I clinical study.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se (anders.vahlne@ki.se)

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and
ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus
infections, i.e. chronic infections with jaundice causing viruses which
can lead to liver cirrhosis and liver cancer. ChronTech has also
developed and further develops a patent pending new type of injection
needle for a more effective uptake of DNA vaccines. ChronTech also have
part ownership in the wound healing therapy ChronSeal®, and in the new
platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se (http://www.chrontech.se/)

In the event of any discrepancy between the Swedish and English versions
of this press release, the Swedish version will take precedence.